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Lamivudine has been shown to be effective in patients
with hepatitis B e antigen (HBeAg)-positive chronic hepati-
tis B, but its long-term efficacy and the rate of resistant
mutations in patients with HBeAg-negative chronic hepati-
tis B is less clear. Twenty-nine patients with HBeAg-negative
chronic hepatitis B, who have received lamivudine for at
least 1 year were studied to determine the antiviral re-
sponse, the rate and pattern of lamivudine-resistant muta-
tions, and the effect of lamivudine-resistant mutations on
HBeAg status. The mean duration of treatment was 21 6 7
months. Before treatment, core promoter variant was de-
tected in 16 (55%) patients and precore stop codon variant
in 18 (62%) patients. Serum hepatitis B virus (HBV) DNA
was detected by solution hybridization assay in 62%, 4%,
and 24% and by polymerase chain reaction (PCR) assay
in 100%, 31%, and 40% at months 0, 6, and 24, respec-
tively. The cumulative rates of detection of lamivudine-
resistant mutations after 1 and 2 years of treatment were
10% and 56%, respectively. In addition to the duration of
treatment, core promoter mutation was associated with the
selection of lamivudine-resistant mutants. Three patients
with lamivudine-resistant mutations had reversion of the
precore stop codon mutation; in 2 patients this was accom-
panied by the reappearance of HBeAg. We found that lami-
vudine-resistant mutants were detected at similar rates in
patients with HBeAg-negative as in patients with HBeAg-
positive chronic hepatitis B. Additional changes in other
parts of the HBV genome may restore the replication fitness
of lamivudine-resistant mutants. (HEPATOLOGY 2000;32:
1145-1153.)
The approval of lamivudine has revolutionized the treat-
ment of chronic hepatitis B. Lamivudine is an orally ad-
ministered nucleoside analog with an excellent safety profile.
Clinical trials in patients with hepatitis B e antigen (HBeAg)-
positive chronic hepatitis B have reported rates of HBeAg to
antibody (anti-HBe) seroconversion in 16% and 17% patients
after 1 year of lamivudine treatment compared with 4% and
6% in controls.1,2 Lamivudine has also been evaluated in pa-
tients with decompensated cirrhosis3 or recurrent hepatitis B
after liver transplantation (LT)4,5 although its use in these
conditions is still experimental.
The greatest drawback with lamivudine treatment is the
selection of drug-resistant hepatitis B virus (HBV) mutants.
Genotypic resistant mutations have been detected in 14% to
32% of patients after 1 year of treatment1,2,6 increasing to 38%,
49%, and 66% after 2, 3, and 4 years of treatment, respective-
ly.7-9 The most common mutation affects the highly con-
served YMDD motif in the catalytic domain of the HBV reverse
transcriptase/DNA polymerase (P gene), resulting in a methi-
onine to valine or isoleucine substitution at codon 552
(M552V or M552I).10 In vitro studies showed that either mu-
tation alone can confer resistance to lamivudine but the
M552I mutant is significantly more resistant to lamivudine
than the M552V mutant.10,11 Another mutation involving a
leucine to methionine substitution at codon 528 (L528M) has
been reported. The L528M mutant alone confers very little
resistance to lamivudine but the combination of L528M and
M552V mutation is more resistant than M552V alone and
similar to that of M552I.10-12 Similar mutations have been
found in patients who received lamivudine treatment for hu-
man immunodeficiency virus (HIV) infection.13 In these pa-
tients, the M184I mutant is transiently detected during the
first few weeks of treatment and then replaced by the M184V
mutant14 because the latter mutant has greater replication
fitness.15,16 The pattern and evolution of lamivudine-resistant
HBV mutations is less well described. Published reports of big
clinical trials described the rates of detection of “YMDD mu-
tant” but did not specify the type of mutation(s).1,2,6,17 In
many instances, genotypic resistant mutation(s) were tested
at one time point, and mutations affecting other regions of the
HBV P gene were not reported.
Most clinical trials on lamivudine treatment have focused
on HBeAg-positive patients. A few studies have reported a
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beneficial effect of lamivudine in patients with HBeAg-nega-
tive chronic hepatitis B, but the effect was not maintained
when treatment was withdrawn. The rates of genotypic resis-
tant mutations in HBeAg-negative patients are more contro-
versial varying from 0 to 18% after 12 to 18 months of treat-
ment.17-19 Several factors may account for the differences in
rates of lamivudine-resistant mutants in these studies: sample
size, ethnic background, viral load, HBV genotype, and prev-
alence of core promoter and precore HBV variants.
We detected lamivudine-resistant mutations in a high per-
cent of Italian patients who were receiving lamivudine for
HBeAg-negative chronic hepatitis B in a pilot study. In addi-
tion, we observed that breakthrough infection caused by lami-
vudine-resistant mutation was sometimes accompanied by re-

















No. (%) HBV DNA Positive
Hyb PCR
I 8 8/0 53 6 6 0 (0) 7 (88) 164 6 147 5/8 (63) 8 (100)
II 21 18/3 49 6 8 0 (0) 21 (100) 190 6 105 13/21 (62) 21 (100)
Total 29 26/3 50 6 8 0 (0) 28 (97) 183 6 116 18/29 (62) 29 (100)
Abbreviation: Hyb, solution hybridization assay.

































mL) PCR 528 552
Group I
1 D 55 273 A G G 5/18 23 2 ND 2 13 * * *
2 D 7 70 A G G 4/18 22 2 ND 2 22 * * *
3 A 9 158 A A G (TGA) 2/25 27 2 ND 2 14 * * *
4 D ND 103 A G A 8/15 23 2 ND 2 11 * * *
5 D ND 52 A G A 7/8 15 2 ND 2 41 * * *
6 D 6 161 T A A 9/12 21 2 ND 2 13 * * *
7 D 905 471 T A A 0/38 38 1 176 1 80 G M V
8 D ND 21 T A A 4/20 24 2 ND 2 19 A† M‡ V‡
Mean 6 SD 164 6 147 24 6 7 27 6 24
Group II
9 D ND 300 A G G 34 2 ND 2 27 * * *
10 D ND 153 A G G 18 2 ND 2 14 * * *
11 A 22 371 T A G 13 2 ND 2 30 * * *
12 A ND 169 T A G 12 2 ND 2 30 * * *
13 D ND 50 T A G 15 2 ND 2 16 * * *
14 D ND 168 A G A 12 2 ND 2 23 * * *
15 D 33 302 A G A 25 2 ND 2 21 * * *
16 D 7 189 A G A 18 2 ND 2 50 * * *
17 C 13 266 A G A 22 2 ND 2 16 * * *
18 D 5 380 A G A 19 2 ND 2 29 * * *
19 D ND 298 T A A 12 2 ND 1 33 A L M
20 D 54 134 T A A 13 2 ND 2 27 * * *
21 D 13 104 T A A 15 2 ND 2 45 * * *
22 D ND 296 T A G 19 2 ND 2 26 * M‡ V‡
23 C ND 161 A G A 25 2 ND 1 64 A M V
24 D 4 106 T A A 31 2 ND 1 34 A M I
25 D 15 169 T A A 32 2§ 10 1 90 A† M I
26 D 15 109 T A A 21 2 36 1 106 A M I
27 D 11 206 T A A 16 2 ND 1 114 A L I
28 D 28 10 T A G 20 2 ND 1 6 G M V
29 D 10 52 T A G 19 1 6 1 37 G L I
Mean 6 SD 190 6 105 20 6 7 40 6 30
Abbreviations: Hyb, solution hybridization assay; CP, core promoter; nt, nucleotide; aa, amino acid; ND, not detected; NT, not tested.
* Sequence not determined, sample PCR negative.
† Transient reversion from A to G at nt 1,896.
‡ Transient detection of lamivudine-resistant mutations.
§ Transient reversion to HBeAg positivity.
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appearance of HBeAg. These observations prompted us to
conduct a systematic study of the entire cohort of HBeAg-
negative patients who were receiving lamivudine therapy to
determine (1) the antiviral response to lamivudine therapy in
patients with HBeAg-negative chronic hepatitis B, (2) the rate
and pattern of lamivudine resistance mutations in HBeAg-
negative patients receiving lamivudine therapy and the risk
factors associated with the selection of these mutants, and (3)
the effect of lamivudine-resistant mutations on HBeAg status
and sequences in the core promoter and precore regions.
PATIENTS AND METHODS
Patients. Twenty-nine patients with chronic hepatitis B, who have
received lamivudine for at least 1 year at the Liver Clinic, Semeiotica
Medica, University of Bologna, Italy, were studied. All the patients
were HBeAg negative and 28 (97%) patients were anti-HBe positive
before treatment. There were 26 men and 3 women, with a mean age
of 50 6 8 years (range, 27-61 years) (Table 1). Group I included 7
patients with decompensated cirrhosis, who received lamivudine
pre- and post-LT and 1 patient (patient 7) who received lamivudine
for recurrent hepatitis B post-LT. The 7 patients with decompensated
cirrhosis also received hepatitis B immune globulin post-LT.20
Group II included 21 patients with histologically proven chronic
hepatitis B with or without cirrhosis. Group I patients received lami-
vudine in doses of 100 mg daily. Group II patients received 150-mg
doses because the 100-mg tablets were not available when this study
began. All the patients had detectable serum HBV DNA by polymer-
ase chain reaction (PCR) assay, 18 (62%) patients also had detectable
serum HBV DNA by solution hybridization assay before treatment
(Table 1). The mean 6 SD duration of treatment was 21 6 7 months
(median, 20; range, 12-38 months). One patient in Group I (patient
2) was also positive for hepatitis C and hepatitis D antibodies. All the
patients were negative for antibody to HIV.
Materials. Serial sera pretreatment and at 3- to 6-month intervals
during treatment were tested for liver biochemistry, HBeAg, anti-
HBe, hepatitis B surface antigen (HBsAg), and HBV DNA. Pretreat-
ment samples from all patients and all subsequent samples that were
HBV-DNA positive by PCR assay were examined for HBV core pro-
moter and precore as well as polymerase gene sequence variations.
Serology Assays. Serology markers for HBV (HBsAg, HBeAg, and
anti-HBe), for hepatitis C (anti-HCV), for hepatitis D (anti-HDV),
and for HIV (anti-HIV) were tested by commercially available en-
zyme immunoassay kits (EIA; Abbott Diagnostics, North Chicago,
IL).
HBV DNA Assays. Serum HBV DNA was detected using a solution
hybridization assay (Abbott Diagnostics), which has a detection limit
of 1.6 pg/mL as well as an in-house PCR assay that has a detection
limit of 250 to 500 genome copies/mL.21
DNA Extraction, PCR Amplification, and Direct Sequencing. DNA ex-
traction, PCR amplification, and direct sequencing of the core pro-
moter and precore regions were performed as described previously
using primers P1, P2, P3, and P4.22 For amplification of P and over-
lapping S gene, the external primers used were SS1 and SAS1 and the
internal primers were SS2 and SAS2.23 All necessary precautions to
prevent cross-contamination were observed and negative controls
were included at each step.
Amplified PCR products were purified by QIAquick spin columns
(Qiagen Inc., Chatsworth, CA) according to the manufacturer’s in-
structions. Purified HBV DNA was directly sequenced by the DNA
sequencing core facility at the University of Michigan Medical Center
using the standard protocol for the Applied Biosystems DNA Se-
quencer 377 (Perkin Elmer Corp., Foster City, CA) using primers P3
and P4 for the core promoter and precore regions and SS2 and SAS2
for the P gene.
HBV Genotyping. HBV genotyping was determined by comparing
the sequences in the HBV S gene with published sequences.24
Cloning. To determine if changes in the P gene and the precore
region during lamivudine treatment occurred in the same genome,
PCR-amplified HBV DNA from serial samples of 3 patients were
cloned and sequenced. HBV genome amplification was performed
using 10 mL DNA extract in the Expand High Fidelity Assay (Boehr-
inger Mannheim, Indianapolis, IN) according to the manufacturer’s
instructions. The reactions were performed with an initial denatur-
ation step at 94°C for 2 minutes; 10 cycles at 94°C for 40 seconds,
60°C for 1.5 minutes, and 68°C for 4 minutes; followed by 30 cycles
at 94°C for 40 seconds, 60°C for 1.5 minutes, 68°C for 4 minutes with
an increment of 5 seconds per cycle, and a 7-minute extension step at
72°C at the end. The external primers were: P5 (59-TTTTTCAC-
CTCTGCCTAATCA-39 1821-1841) and P6 (59-AAAAAGTTGCAT-
GGTGCTGG-39 1825-1806). The second round PCR used hemi-
nested primers P5 and SAS1.
The amplified products were used fresh (within 24 hours) for
ligation with the pCR2.1 vector (Invitrogen Corp., San Diego, CA) at
14°C overnight according to the manufacturer’s instructions.
TOP10F9-competent Escherichia coli (Invitrogen Corp.) was used for
transformation. Transformed bacteria were selected by plating on
Luria-Bertoni agar in the presence of ampicillin (50 mg/mL), X-Gal
(1.6 mg/mL), and IPTG (0.4 mmol/L). Clones containing the HBV
DNA insert were selected based on their white color and were grown
FIG. 1. Antiviral response during lamivudine treatment. (p) PCR; ( )
solution hybridization assay.




M552V or M552I P
Pretreatment HBV DNA
Solution hybridization assay 1 7/18 (39) NS
Solution hybridization assay 2 3/11 (27)
Group I 2/8 (25) NS
Group II 8/21 (38)
HBV genotypes
A 0/3 (0) NS
C 1/2 (50)
D 9/24 (38)
Precore eW28X/G1896A variant 1 7/18 (39) NS
Precore eW28X/G1896A variant 2 3/11 (27)
Core promoter A1762T/G1764A
variant 1 9/16 (56) .01
Core promoter A1762T/G1764A
variant 2 1/13 (8)
Duration of treatment (months) #18 1/10 (10) .05
Duration of treatment (months) .18 9/19 (47)
Abbreviation: NS, not significant.
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TABLE 4. Serial Changes in HBeAg Status, HBV DNA and ALT Levels, and Precore and P Gene Sequences













528 552 Other Changes
7 0 2 905 471 A L M
6/6 clones A L M
3 2 ND 65 A L M N437Y N602I
sL80F
7 2 698 60 G M V N437Y A548V L577M N602I
sI195M sL192F sF220L
5/5 clones G M V N437Y A548V L577M N602I
14 1 238 173 G M V N437Y A548V L577M N602I
26 1 204 85 G M V N437Y A548V L577M N602I
39 1 176 80 G M V N437Y A548V L577M N602I
5/5 clones G M V N437Y A548V L577M N602I
8 0 2 ND 21 A L M
3 2 ND 24 A L M N496Y T585P
sX139C
10 2 ND 12 A M V N496Y W501R L577A T585P
sI195M
22 2 ND 18 A M V N496Y W501R L577A T585P
24 2 ND * * *
22 0 2 ND 296 G L M
9 2 ND 26 G L M
11 2 ND 26 G M V
sI195M
15 2 ND 25 * * *
19 2 ND 26 * * *
23 0 2 ND 161 A L M
14 2 ND 25 A L M
16 2 ND 34 * * *
22 2 ND 38 A M V N496Y K497Q I572V
sI195M sX139C
26 2 ND 64 A M V . M N496Y K497Q I572V
24 0 2 4 106 A L M
14 2 ND 44 * * *
19 2 ND 67 * * *
29 2 ND 34 A M I F492L M493L P585H
sW196L
31 2 ND 35 A M I F492L M493L P585H
25 0 2 15 169 A L M
10/10 clones A L M
2 2 5 48 A/G L M
4 2 ND 35 G M I K560T
sW196L sS204R
5/5 clones G M I K560T
10 2 10 30 A L I S491T K560T
sF134L
12 1 10 225 G M I S491T K560T
9/9 clones G M I S491T K560T
20 1 18 104 G M I S491T K560T
26 2 10 90 G . A M I S491T K560T
32 2 5 291 A M I S491T K560T
10/10 clones A M I S491T K560T
26 0 2 15 109 A L M
7/7 clones A L M
6 2 ND 29 A L M
9 2 ND 47 A L I
sW196L
12 2 5 219 A L/M I N470L N472H Q478P
sT114S sK122R
3 clones A L I N470L N472H Q478P
2 clones A M I N470L N472H Q478P
15 2 44 90 A L/M I N470L N472H Q478P
21 2 36 106 A M . L I N470L N472H Q478P
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overnight at 37°C in 5 mL of Luria-Bertoni broth containing 50
mg/mL ampicillin. Recombinant plasmids were recovered using the
QIAprep-8 miniprep kit (Qiagen Inc.) following the manufacturer’s
instructions. Purified plasmids were digested with the restriction
enzymes HindIII and NotI (Gibco BRL, Grand Island, NY). Plasmids
containing the 2.2-kb insert, which spanned the core promoter and
precore regions and domains A-E of the HBV reverse transcriptase/
polymerase gene were sequenced using the primers M13 Reverse
(59-CAGGAAACAGCTATGACC-39) andT7 (59-TAATACGACT-
CACTATAGGG-39) on pCR2.1 vector.
Statistical Analyses. Two-tailed Student’s t test was used to com-
pare continuous variables. x2 test with Yates correction was used to
compare categorical data.
RESULTS
HBV Genotypes and Baseline Core Promoter, Precore, and P Gene
Sequences. Sequence alignment showed that HBV genotypes
A, C, and D were present in 3, 2, and 24 patients, respectively
(Table 2). Before the initiation of lamivudine treatment, the
dual core promoter variant A1762T, G1764A was detected in 16
(55%) patients and the precore stop codon variant (G to A
change at nucleotide 1,896 in the precore region resulting in
conversion of tryptophan to stop codon at position 28 in
HBeAg, eW28X/G1896A) in 18 (62%) patients (Table 2). Ten
(34%) patients had both core promoter and precore muta-
tions. Another precore stop codon variant eW28X/G1897A was
found in 1 patient (patient 3). The predominant sequence at
positions 528 and 552 of the HBV polymerase protein was
leucine and methionine in all patients.
Antiviral Response. A decrease in viral load was observed in
the vast majority of patients. The proportion of patients who
had detectable serum HBV DNA decreased from 62% at
month 0 to 4% at month 6 (P , .0001) when tested by solu-
tion hybridization assay and from 100% to 31% (P , .0001)
when tested by PCR assay (Fig. 1). However, lamivudine-
resistant mutations began to emerge after month 4. Thus, the
proportion of patients who had detectable serum HBV DNA
increased as treatment continued (Fig. 1).
Of the 18 patients who had detectable serum HBV DNA by
solution hybridization assay before treatment, most had low
serum HBV DNA levels, only one had HBV DNA level greater
than 100 pg/mL. During treatment, HBV DNA became unde-
tectable by solution hybridization assay in all patients. How-
ever, breakthrough infection defined as reappearance of se-
rum HBV DNA by solution hybridization assay after its initial
disappearance was observed in 6 (33%) patients. Serum HBV
DNA remained detectable in 4 of these 6 patients at the last
follow-up.
In the remaining 11 patients, HBV DNA became undetect-
able by PCR assay in 10 (91%) patients initially but reap-
peared in 1 patient as treatment continued (patient 23). None
of these 11 patients had detectable serum HBV DNA by solu-
tion hybridization assay throughout the study.
None of the patients cleared HBsAg.
Detection of Lamivudine-Resistant Mutations. Lamivudine-re-
sistant mutations involving the YMDD motif were detected in
10 (35%) patients, 7 (39%) of 18 patients who had detectable
HBV DNA and 3 (27%) of 11 patients who had undetectable
HBV DNA by solution hybridization assay before treatment
(Table 3). There was no correlation between HBV genotypes,
presence or absence of the precore stop codon variant, and
detection of lamivudine-resistant mutants. Lamivudine-resis-
tant mutations were more often found in patients with the
dual core promoter variant and in those who had longer du-
ration of treatment (Table 3).
The mean interval from onset of treatment to the first de-
tection of these mutations was 13 months (median, 10.5














528 552 Other Changes
4 clones A M I N470L N472H Q478P
3 clones A L I N470L N472H Q478P
27 0 2 11 206 A L M
6 2 ND 62 A L I
sW196L
9 2 8 52 A L I S401N Y402H L428G A562E
sS45T sP46T
16 2 ND 114 A L I S401N Y402H L428G A562E
28 0 2 28 10 G L M
13 2 ND 15 G L M I591M
sX163W
16 2 ND 4 G M V Q497K R501W I519M
sI195M
20 2 ND 6 G M V Q497K R501W I519M
29 0 2 10 52 G L M
9 2 ND 30 G L M
12 2 ND 26 G L I
sW196L
19 1 6 37 G L I
NOTE. Corresponding changes in overlapping S gene are indicated beneath the P gene changes, changes in P gene that result in reversion to predominant
P gene sequence for that particular HBV genotype are underlined. Abbreviations for changes in overlapping S gene are denoted with small letter s to indicate
surface gene, e.g., M552V in P gene results in isoleucine to methionine substitution in position 195 of S gene (sI195M).
Abbreviations: nt, nucleotide; ND, not detected; NA, sample not available.
* Sequence not determined, sample PCR negative.
HEPATOLOGY Vol. 32, No. 5, 2000 LOK ET AL. 1149
of detection of lamivudine-resistant mutations at the end of
1 and 2 years of treatment were 10% and 56%, respectively
(Fig. 2).
The 10 patients with lamivudine-resistant mutations have
been followed for a mean of 12 6 10 months (range, 2-32
months). Despite the emergence of these mutations, only 5
patients (patients 7, 25, 26, 27, and 29) had detectable serum
HBV DNA by solution hybridization assay (Table 4), 3 of
whom had elevated alanine transaminase (ALT) levels. In the
remaining 5 patients, only 1 (patient 23) had elevated ALT
levels. All 10 patients with lamivudine-resistant mutations
had stable liver disease with no evidence of hepatic decom-
pensation.
Five (50%) patients were found to have the M552V mutant,
and all had accompanying L528M mutation, which was de-
tected simultaneously with the M552V mutant (Table 4). Sub-
sequent samples from 2 of these 5 patients (patients 8 and 22)
became undetectable for HBV DNA by PCR assay. Five pa-
tients were found to have the M552I mutant. In 2 patients
(patients 24 and 25), the L528M mutation was detected si-
multaneously with the M552I mutant. In 1 patient (patient
26), the L528M mutation was detected 3 months after the first
detection of the M552I mutant. In the other 2 patients (pa-
tients 27 and 29), the L528M mutation was not detected 10
and 7 months after the first detection of the M552I mutant.
The M552V and M552I mutations result in amino acid sub-
stitutions in the overlapping S gene, isoleucine to methionine
at position 195 (sI195M), and tryptophan to leucine at posi-
tion 196 (sW196L), respectively; whereas the L528M muta-
tion is silent in the S gene.
Changes in Precore and HBeAg Status in Association With the
Emergence of Lamivudine-Resistant Mutations. Of the 10 patients
with lamivudine-resistant mutations, 3 (patients 7, 8, and 25)
had reversion of the precore stop codon mutation to trypto-
phan at codon 28 (A to G at nucleotide 1896) (Tables 2 and 4).
In 1 patient (patient 7), the reversion in the precore sequence
was simultaneous with the first detection of the M552V mu-
tant and accompanied by persistent detection of HBeAg and
high serum HBV DNA levels (Fig. 3A). In the second patient
(patient 25), reversion in the precore sequence was simulta-
neous with the first detection of the M552I mutant but ap-
pearance of HBeAg occurred 8 months later (Fig. 3B). This
patient subsequently became HBeAg negative again with re-
appearance of the precore stop codon mutation. Serum HBV-
DNA levels were higher during the period when the patient
was HBeAg positive. The third patient (patient 8) had tran-
sient reversion in the precore sequence but remained HBeAg
negative and serum HBV DNA was persistently undetectable
by solution hybridization assay (Fig. 3C). An additional pa-
tient (patient 29) became HBeAg positive with reappearance
of low serum HBV-DNA levels. This latter patient did not have
the precore stop codon mutation initially. No change in pre-
core sequence accompanied the appearance of HBeAg.
To determine if changes in the precore and P gene se-
quences occurred in the same genome, serial (3-4) samples
from 3 patients (patients 7, 25, and 26) were cloned and mul-
tiple (5-10) clones at each time point were sequenced. In all 3
patients, changes in the precore and P gene sequences were
detected in the same clones (Table 4).
None of the patients had detectable changes in the core
promoter sequence during the study.
Other Changes in the P Gene. Eight of the 10 patients who had
mutations in the YMDD motif were observed to have addi-
tional changes in the P gene (Table 4). Most of these changes
emerged at the same time when the M552V or M552I mutants
were first detected. Only one of the 25 changes, N496Y, was
detected in more than one patient (patients 8 and 23). In these
2 patients, the pretreatment samples had asparagine at posi-
tion 496 in the P gene and stop codon at position 139 in the
overlapping S gene. During treatment, the sequence at this
position reverted back to the predominant/reference se-
quence, tyrosine at 496 in the P gene and cysteine at 139 in the
S gene. Because position 139 in the S gene is located in the “a”
determinant, the predominant epitope of HBsAg, multiple
clones from the pretreatment samples of these 2 patients were
sequenced. Tyrosine at position 496 in the P gene and cysteine
at 139 in the S gene were found in 4 of 9 clones in patient 8 and
in 2 of 7 clones in patient 23. Ten of the remaining 24 changes
in the P gene resulted in changes in the overlapping S gene.
Of these, 4 resulted in unique amino acid changes in the S
gene, one in the “a” determinant (patient 25, pS491T/sF134),
and the other 3 in the transmembrane domain of HBsAg
(patient 7, pA548V/sL192F, pL577M/sF220L; patient 25
pK560T/sS204R). The remaining 6 changes were reversions
back to the predominant/reference sequence.
DISCUSSION
In this study, we confirmed that lamivudine therapy is ef-
fective in inhibiting HBV replication in patients with HBeAg-
negative chronic hepatitis B. Although HBeAg-negative
chronic hepatitis B in Mediterranean countries has been
equated with the presence of precore stop codon mutation,
the classic eW28X/G1896A variant was only detected in 62% of
our patients, all of whom were Italians. An antiviral response
was observed in patients with precore stop codon mutation
(eW28X) alone, core promoter mutation (A1762T, G1764A)
alone, combined precore and core promoter mutations, or
wild-type precore/core promoter sequence. Because of the
small number and the heterogeneity of the patients, we cannot
determine if there is any correlation between antiviral re-
sponse and HBV precore/core promoter sequence.
FIG. 2. Cumulative rates of detection of lamivudine-resistant M552V/I
mutants. Number of patients at risk are listed at the bottom.
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Genotypic resistance to lamivudine was detected in 10
(35%) patients after a mean of 22 6 7 months of treatment.
The cumulative rates of detection of M552V/I mutations after
1 and 2 years of treatment were 10% and 56%, respectively.
Compared with other studies on patients with HBeAg-nega-
tive chronic hepatitis B, the rate of genotypic resistance after 1
year of treatment was similar to that reported by Santantonio
et al.18 and lower than Tassopoulos et al.17 Despite the detec-
tion of genotypic resistance, only 50% of our patients had
detectable serum HBV DNA by solution hybridization assay
and only 40% had elevated ALT levels. All 10 patients contin-
ued to have stable liver disease after a mean follow-up of 12 6
11 months. The favorable outcome of these patients may be
related to the decreased replication fitness of the lamivudine-
resistant mutants.25,26 Two patients with M552V subse-
quently had undetectable serum HBV DNA by PCR assay.
Disappearance of lamivudine-resistant mutants and HBeAg
seroconversion after the detection of genotypic resistance
have been reported in HBeAg-positive patients.27
In addition to the duration of treatment, we found that core
promoter mutations were more likely to be associated with
the selection of lamivudine-resistant mutants. The exact rea-
son(s) for this association is not clear. In this study, presence
of the precore stop codon mutation did not correlate with the
selection of lamivudine-resistant mutants.
Half of our patients with genotypic resistance to lamivudine
had M552V and the other half had M552I mutation. Previous
studies suggested that M552V was the predominant mutant
among patients with lamivudine-resistant HBV mutations and
that L528M was only found in association with M552V.10,28
However, a review of the literature found that M552V and
M552I were detected in similar proportions of hepatitis B
patients with lamivudine resistance and the combination of
L528M and M552I had been reported in 2 patients (Table
5).29-31 In this study, L528M was detected simultaneously
with M552V in 5 patients, simultaneously with M552I in 2
patients, delayed for 3 months in 1 patient with M552I, and
not detectable 7 and 10 months after the detection of M552I in
2 patients. The more frequent association of L528M and
M552V may be related to the fact that M552V alone confers
less resistance to lamivudine than M552I. In vitro studies com-
paring the antiviral effects of lamivudine in transfected hepa-
tocyte cell lines showed increasing order of resistance with
L528M , M552V , L528M 1 M552V and M552I.10,11 Thus,
the addition of L528M to M552V may be necessary for in vivo
resistance to lamivudine. Several studies have shown a de-
TABLE 5. Patterns of Mutations in the Reverse Transcriptase/DNA
Polymerase Domain in Patients Receiving Lamivudine Therapy
Reference












Liaw et al.27 12 0 0 20
McCaughan et al.33 6 0 0 0
Hussain and Lok29* 28 3 2 15
Current 5 0 3† 2
Total 51 3 5 37
* Review of published data.
† In 1 patient L528M detected 3 months after detection of M552I.
FIG. 3. Serial changes in serum HBV DNA (■) and ALT (}) levels in 3
patients who had lamivudine-resistant M552V/I with or without L528M mu-
tations and reversion of the precore stop codon to tryptophan at position 28
(A to G at nucleotide 1,896). In one patient (patient 7), reversion in precore
sequence was accompanied by persistent reappearance of HBeAg and high
serum HBV DNA levels (A). In the second patient (patient 25), reversion in
the precore sequence and reappearance of HBeAg was transient. Serum HBV
DNA levels were higher when the patient became HBeAg positive (B). The
third patient (patient 8) had transient reversion in precore sequence but
remained HBeAg negative with undetectable serum HBV DNA by solution
hybridization assay (C).
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crease in replication fitness of M552V and M552I compared
with “wild-type” HBV and a partial restoration in replication
fitness with the addition of L528M.25,26 It is possible that the
subsequent selection of L528M in some patients with M552I
serve to restore replication fitness rather than to increase re-
sistance to lamivudine. The infrequent report of the combined
mutations L528M and M552I may be related to sampling time
and the fact that most studies tested for resistant mutants at
one time point only. The additional selection of L528M in
some patients with M552I during continued treatment with
lamivudine was also observed in one recent study.32
Three patients with lamivudine-resistant mutations had re-
version of the precore stop codon mutation. The exact rea-
son(s) for the reversion of the precore stop codon mutation in
these 3 patients is not clear. The time relationship between the
detection of the lamivudine-resistant mutations and the rever-
sion in the precore sequence, and the fact that these changes
occurred in the same genomes suggest that the changes in
polymerase and precore regions may be related. It is possible
that the reversion of the precore stop codon mutation restores
the replication fitness of the lamivudine-resistant mutants.
This accounts for the higher serum HBV DNA levels when the
patients reverted from A to G at nucleotide 1,896 and became
HBeAg positive.
Eight of the 10 patients who had M552V/I mutations had
additional changes in the P gene. However, the significance of
these changes is not clear because there was no consistent
pattern and most of the changes were detected at the same
time as the M552V/I mutants. Approximately half of the
changes in the P gene resulted in amino acid substitutions in
the overlapping S gene. Previous studies found that M552V/I
do not affect HBsAg secretion25 but the impact of other P gene
changes on virion production, HBsAg secretion, and antige-
nicity is unknown.
In this study, we have systematically characterized the
evolution of HBV core promoter, precore, and reverse tran-
scriptase/polymerase sequences in a cohort of patients with
HBeAg-negative chronic hepatitis B, who have received
lamivudine therapy for at least 1 year. An initial antiviral
response was obtained in patients with or without precore/
core promoter variants. Genotypic resistance to lamivudine
was detected at similar rates as in HBeAg-positive patients.
In addition to the duration of treatment, core promoter
mutations were more likely to be associated with lamivu-
dine resistance. However, further studies with larger num-
bers of patients from different geographical areas are
needed to confirm this observation and to determine if
there is any correlation between HBV genotypes, precore,
and core promoter variants and response to lamivudine
therapy. Contrary to most published reports, we found
that L528M may be found in association with M552I, albeit
at a later stage. The most important finding in our study is
the reversion of precore stop codon mutation and reappear-
ance of HBeAg in some of our patients who had genotypic
resistance to lamivudine. Our findings suggest that in pa-
tients with genotypic resistance to lamivudine, additional
changes may be selected to restore replication fitness of
HBV. These changes may be found outside the polymerase/
reverse transcriptase domain of the HBV genome.
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